Filing Flows › Longevity Health Holdings (XAGE) › Q2 2026 › vs Q2 2025
Longevity Health Holdings (XAGE) Q2 2026 vs Q2 2025 (year over year)
Longevity Health Holdings's revenue fell $108K (-21%) from $504K in Q2 2025 to $396K in Q2 2026.
Longevity Health Holdings, Q2 2026: revenue $396K (-21% year over year), operating margin -182.9%, net loss $1.9M, operating cash flow −$224K. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $396K | $504K | −$108K | -21% |
| Net loss | $1.9M | $1.9M | −$3K | -0.2% |
| Costs & expenses | $2.3M | $2.4M | −$111K | -5% |
| Operating costs | $1.1M | $2.4M | −$1.2M | -53% |
| Interest & other, net | $1.2M | $28K | $1.1M | 42× |
| Cost of revenue | $160K | $201K | −$40K | -20% |
| Research & development | $73K | $229K | −$155K | -68% |
| Sales & marketing | $191K | $346K | −$154K | -45% |
| General & admin | $682K | $1.6M | −$883K | -56% |
| Other operating costs | $13K | $22K | −$9K | -40% |
| Operating cash sources | $1.9M | $1.9M | −$3K | -0.2% |
| Depreciation & amortization | $13K | $22K | −$9K | -40% |
| Share-based compensation | $79K | $194K | −$116K | -59% |
| Working capital & other | $1.6M | $834K | $734K | +88% |
| Cash used in operations | $224K | $836K | −$612K | -73% |
| Net loss absorbed | $1.9M | $1.9M | −$3K | -0.2% |
Questions
How much did Longevity Health Holdings's revenue grow year over year in Q2 2026?
Longevity Health Holdings's revenue fell $108K (-21%) from $504K in Q2 2025 to $396K in Q2 2026.